Crest Clinical Study Supports Triclosan Antigingivitis Efficacy – Ciba
This article was originally published in The Rose Sheet
Executive Summary
A clinical trial conducted in China on a triclosan-containing toothpaste marketed under the Crest brand demonstrates an improvement in the bleeding index of subjects, supporting the ingredient's antigingivitis efficacy, Ciba states in an Oct. 1 1submission to FDA
You may also be interested in...
Ciba Triclosan Application Does Not Meet TEA Criteria, Colgate Argues
Triclosan should not be included as a Category I active in the antigingivitis OTC drug products monograph because data does not prove the ingredient meets the criteria for time and extent exclusion from FDA's definition of a new drug, Colgate-Palmolive maintains in Aug. 16 comments to the agency
Ciba Triclosan Application Does Not Meet TEA Criteria, Colgate Argues
Triclosan should not be included as a Category I active in the antigingivitis OTC drug products monograph because data does not prove the ingredient meets the criteria for time and extent exclusion from FDA's definition of a new drug, Colgate-Palmolive maintains in Aug. 16 comments to the agency
Triclosan Antigingivitis Effectiveness Data Questioned By P&G, Colgate
Data evaluating the efficacy of triclosan as an antigingivitis ingredient do not support its inclusion as a Category I active in the OTC Antigingivitis/ Antiplaque Monograph, according to the oral care industry's two leading marketers, Procter & Gamble and Colgate-Palmolive